CTIS2023-509841-12-00进行中（未招募）1 期
01/2023/Pozlab
Cepha s.r.o.0 个研究点目标入组 14 人开始时间: 2023年12月19日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteersPrevention of atherothrombotic events in adult patients with- acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventMedDRA version: 20.0Level: PTClassification code: 10028596Term: Myocardial infarction Class: 100000004849CTIS2023-504116-14-00Celon Pharma S.A.40
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.CTIS2024-512773-27-00Sun Pharmaceutical Industries Limited54
进行中（未招募）
1 期
A Single Dose, Fed state, Crossover Replicate Bioequivalence Study of NITROFURANTOIN 100 mg prolonged-release capsules (Iasis Pharma) vs. FURABID® 100 mg prolonged-release capsules (Amdipharm Limited)healthy subjectsCTIS2023-503887-18-00Antibiotice S.A.32
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersdiabetes mellitushypertensionCTIS2024-511526-31-00Celon Pharma S.A.38
招募中
1 期
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTSmetabolic bone diseasesMedDRA version: 20.0Level: SOCClassification code: 10028395Term: Musculoskeletal and connective tissue disorders Class: 17CTIS2023-503866-22-00Mesentech Inc.72